Agios Pharmaceuticals Stock News

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 2.16% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

– Completed Regulatory Submissions for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. and EU –

Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase deficiency.

CAMBRIDGE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetic

Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.

CAMBRIDGE, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetic

Agios Pharmaceuticals Inc (NASDAQ: AGIO) has submitted an FDA marketing application seeking approval for mitapivat to treat adults with pyruvate kinase (PK) deficiency. The company says, if approve

CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetic

– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in the U.S. This Quarter and in the EU in Mid-2021 –

With the trading day about halfway over, the markets were moving higher, after being stuck in the doldrums for the first half of the week.

– Agios to Host Investor Webcast on June 11 at 7:30 a.m. ET –

Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.

Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q1 2021 Results - Earnings Call Transcript

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -6.50% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.